Cargando…
1567. Perspectives of People with HIV (PWH) 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND)
BACKGROUND: CAB+RPV LA is the only complete long-acting regimen for treatment of virologically suppressed people with HIV (PWH). Administered monthly or every 2 months by a healthcare provider (HCP), CAB+RPV LA may alleviate challenges associated with daily oral antiretroviral therapy (ART). Perspec...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678594/ http://dx.doi.org/10.1093/ofid/ofad500.1402 |
_version_ | 1785150399088427008 |
---|---|
author | Dandachi, Dima Cunningham, Douglas Valenti, William M Phoenix, John Nguyen, Kaitlin Teichner, Paula Jean-Louis, Ashley Reynolds, Maria Richardson, David Garris, Cindy |
author_facet | Dandachi, Dima Cunningham, Douglas Valenti, William M Phoenix, John Nguyen, Kaitlin Teichner, Paula Jean-Louis, Ashley Reynolds, Maria Richardson, David Garris, Cindy |
author_sort | Dandachi, Dima |
collection | PubMed |
description | BACKGROUND: CAB+RPV LA is the only complete long-acting regimen for treatment of virologically suppressed people with HIV (PWH). Administered monthly or every 2 months by a healthcare provider (HCP), CAB+RPV LA may alleviate challenges associated with daily oral antiretroviral therapy (ART). Perspectives of PWH receiving CAB+RPV LA in real-world US healthcare settings are needed. METHODS: This 2-year prospective, observational study enrolled treatment experienced PWH following the decision to switch to CAB+RPV LA (monthly or every 2 months) across 30 participating US sites. Participants completed baseline (BL) surveys prior to first injection and follow-up surveys at Month 6 (M6). Surveys assessed challenges with daily oral ART, reasons for initiating CAB+RPV LA, HIV treatment satisfaction using the HIV Treatment Satisfaction Questionnaire (HIVTSQ), preference for daily oral vs. injectable, and benefits of more frequent clinic visits. RESULTS: A total of 308 PWH were enrolled and completed BL surveys (Table 1); 217 PWH had reached the M6 timepoint and completed M6 surveys as of data cut-off (Jan 2023); of the 217 PWH, 8 reported they had discontinued CAB+RPV LA. At BL, 49% respondents reported sometimes, often, or always hiding their prior oral ART for fear of disclosing HIV status. The common primary reasons PWH chose to start CAB+RPV LA were: tired of taking daily oral ART, wanted a more convenient treatment option, and worried about missing a dose (Table 2). At M6, PWH receiving CAB + RPV LA reported a decrease from BL in fear of disclosure, anxiety around adherence, and daily reminder of HIV. At M6, 88% of PWH reported CAB+RPV LA was rarely or never an unwelcome reminder of their HIV status vs. 50% at BL with prior oral ART. Most participants preferred CAB+RPV LA (95%), 2% preferred daily oral ART, and 2% had no preference at M6. Treatment satisfaction increased from BL to M6; most reported multiple additional benefits with more frequent clinic visits (Table 3). [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: Switching to CAB + RPV LA demonstrated improvements in fear of disclosure, anxiety around adherence, and daily reminder of HIV status at M6 (Fig. 1-3). PWH reported a strong preference for CAB+RPV LA, increased treatment satisfaction, and more opportunities to engage with their HIV care. [Figure: see text] [Figure: see text] [Figure: see text] DISCLOSURES: Dima Dandachi, MD, MPH, ViiV Healthcare: Advisor/Consultant|ViiV Healthcare: Grant/Research Support Douglas Cunningham, DO, ViiV Healthcare: Advisor/Consultant William M. Valenti, MD, FIDSA, Gilead: Grant/Research Support|ViiV Healthcare: Grant/Research Support John Phoenix, MSN, APRN, FNP-C, Gilead: Grant/Research Support|Gilead: Speaker Bureau|Huntridge Family Clinic: Ownership Interest|Napo Pharmaceuticals: Speaker Bureau|ViiV Healthcare: Grant/Research Support|ViiV Healthcare: Speaker Bureau Paula Teichner, PharmD, GlaxoSmithKline: Stocks/Bonds|ViiV Healthcare: Employment Maria Reynolds, MStat, RTI Health Solutions: Employment|ViiV Healthcare: Grant/Research Support Cindy Garris, MS, GSK: Stocks/Bonds|ViiV Healthcare: Employee |
format | Online Article Text |
id | pubmed-10678594 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106785942023-11-27 1567. Perspectives of People with HIV (PWH) 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND) Dandachi, Dima Cunningham, Douglas Valenti, William M Phoenix, John Nguyen, Kaitlin Teichner, Paula Jean-Louis, Ashley Reynolds, Maria Richardson, David Garris, Cindy Open Forum Infect Dis Abstract BACKGROUND: CAB+RPV LA is the only complete long-acting regimen for treatment of virologically suppressed people with HIV (PWH). Administered monthly or every 2 months by a healthcare provider (HCP), CAB+RPV LA may alleviate challenges associated with daily oral antiretroviral therapy (ART). Perspectives of PWH receiving CAB+RPV LA in real-world US healthcare settings are needed. METHODS: This 2-year prospective, observational study enrolled treatment experienced PWH following the decision to switch to CAB+RPV LA (monthly or every 2 months) across 30 participating US sites. Participants completed baseline (BL) surveys prior to first injection and follow-up surveys at Month 6 (M6). Surveys assessed challenges with daily oral ART, reasons for initiating CAB+RPV LA, HIV treatment satisfaction using the HIV Treatment Satisfaction Questionnaire (HIVTSQ), preference for daily oral vs. injectable, and benefits of more frequent clinic visits. RESULTS: A total of 308 PWH were enrolled and completed BL surveys (Table 1); 217 PWH had reached the M6 timepoint and completed M6 surveys as of data cut-off (Jan 2023); of the 217 PWH, 8 reported they had discontinued CAB+RPV LA. At BL, 49% respondents reported sometimes, often, or always hiding their prior oral ART for fear of disclosing HIV status. The common primary reasons PWH chose to start CAB+RPV LA were: tired of taking daily oral ART, wanted a more convenient treatment option, and worried about missing a dose (Table 2). At M6, PWH receiving CAB + RPV LA reported a decrease from BL in fear of disclosure, anxiety around adherence, and daily reminder of HIV. At M6, 88% of PWH reported CAB+RPV LA was rarely or never an unwelcome reminder of their HIV status vs. 50% at BL with prior oral ART. Most participants preferred CAB+RPV LA (95%), 2% preferred daily oral ART, and 2% had no preference at M6. Treatment satisfaction increased from BL to M6; most reported multiple additional benefits with more frequent clinic visits (Table 3). [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: Switching to CAB + RPV LA demonstrated improvements in fear of disclosure, anxiety around adherence, and daily reminder of HIV status at M6 (Fig. 1-3). PWH reported a strong preference for CAB+RPV LA, increased treatment satisfaction, and more opportunities to engage with their HIV care. [Figure: see text] [Figure: see text] [Figure: see text] DISCLOSURES: Dima Dandachi, MD, MPH, ViiV Healthcare: Advisor/Consultant|ViiV Healthcare: Grant/Research Support Douglas Cunningham, DO, ViiV Healthcare: Advisor/Consultant William M. Valenti, MD, FIDSA, Gilead: Grant/Research Support|ViiV Healthcare: Grant/Research Support John Phoenix, MSN, APRN, FNP-C, Gilead: Grant/Research Support|Gilead: Speaker Bureau|Huntridge Family Clinic: Ownership Interest|Napo Pharmaceuticals: Speaker Bureau|ViiV Healthcare: Grant/Research Support|ViiV Healthcare: Speaker Bureau Paula Teichner, PharmD, GlaxoSmithKline: Stocks/Bonds|ViiV Healthcare: Employment Maria Reynolds, MStat, RTI Health Solutions: Employment|ViiV Healthcare: Grant/Research Support Cindy Garris, MS, GSK: Stocks/Bonds|ViiV Healthcare: Employee Oxford University Press 2023-11-27 /pmc/articles/PMC10678594/ http://dx.doi.org/10.1093/ofid/ofad500.1402 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Dandachi, Dima Cunningham, Douglas Valenti, William M Phoenix, John Nguyen, Kaitlin Teichner, Paula Jean-Louis, Ashley Reynolds, Maria Richardson, David Garris, Cindy 1567. Perspectives of People with HIV (PWH) 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND) |
title | 1567. Perspectives of People with HIV (PWH) 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND) |
title_full | 1567. Perspectives of People with HIV (PWH) 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND) |
title_fullStr | 1567. Perspectives of People with HIV (PWH) 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND) |
title_full_unstemmed | 1567. Perspectives of People with HIV (PWH) 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND) |
title_short | 1567. Perspectives of People with HIV (PWH) 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND) |
title_sort | 1567. perspectives of people with hiv (pwh) 6 months following a switch to cabotegravir and rilpivirine long-acting (cab+rpv la) in an observational real-world us study (beyond) |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678594/ http://dx.doi.org/10.1093/ofid/ofad500.1402 |
work_keys_str_mv | AT dandachidima 1567perspectivesofpeoplewithhivpwh6monthsfollowingaswitchtocabotegravirandrilpivirinelongactingcabrpvlainanobservationalrealworldusstudybeyond AT cunninghamdouglas 1567perspectivesofpeoplewithhivpwh6monthsfollowingaswitchtocabotegravirandrilpivirinelongactingcabrpvlainanobservationalrealworldusstudybeyond AT valentiwilliamm 1567perspectivesofpeoplewithhivpwh6monthsfollowingaswitchtocabotegravirandrilpivirinelongactingcabrpvlainanobservationalrealworldusstudybeyond AT phoenixjohn 1567perspectivesofpeoplewithhivpwh6monthsfollowingaswitchtocabotegravirandrilpivirinelongactingcabrpvlainanobservationalrealworldusstudybeyond AT nguyenkaitlin 1567perspectivesofpeoplewithhivpwh6monthsfollowingaswitchtocabotegravirandrilpivirinelongactingcabrpvlainanobservationalrealworldusstudybeyond AT teichnerpaula 1567perspectivesofpeoplewithhivpwh6monthsfollowingaswitchtocabotegravirandrilpivirinelongactingcabrpvlainanobservationalrealworldusstudybeyond AT jeanlouisashley 1567perspectivesofpeoplewithhivpwh6monthsfollowingaswitchtocabotegravirandrilpivirinelongactingcabrpvlainanobservationalrealworldusstudybeyond AT reynoldsmaria 1567perspectivesofpeoplewithhivpwh6monthsfollowingaswitchtocabotegravirandrilpivirinelongactingcabrpvlainanobservationalrealworldusstudybeyond AT richardsondavid 1567perspectivesofpeoplewithhivpwh6monthsfollowingaswitchtocabotegravirandrilpivirinelongactingcabrpvlainanobservationalrealworldusstudybeyond AT garriscindy 1567perspectivesofpeoplewithhivpwh6monthsfollowingaswitchtocabotegravirandrilpivirinelongactingcabrpvlainanobservationalrealworldusstudybeyond |